Like most startups, Halo looks much different today than it did when we started, but the problem we’re solving hasn’t changed — there are thousands of scientific discoveries that never materialize into real-world solutions. At first, we tried to...
"By conducting a pilot with a startup, large organizations can mitigate risk through a small, controlled test of existing technology applied to their customers and start to show the exciting opportunities that are possible."
Baxter is a Fortune 500 medical device and healthcare company and one of the world’s largest manufacturers of home dialysis machines. Today, Baxter must ship 900 pounds of dialysis solution to every patient each month. Last year Baxter posted...
A 20+ year veteran of global ag giant Syngenta, Stuart Harrison, Phd heads up the company's R&D partnerships and open innovation strategy. Ahead of the World Agri-tech Innovation Summit, where three finalists from Syngenta’s latest startup challenge...
In January, Halo kicked off our program with Baxter (NYSE: BAX), a Fortune 500 medical device company with a focus on kidney disease, immune disorders and other chronic conditions. Baxter was seeking new technologies to purify tap water to make it...
Two months ago on October 12, we celebrating some of the most inspiring scientists in Chicago working to advance their research and help patients. As 2020 draws to a close, take a look back at the names and faces of these heroes and their supporters...
Meet the 40 under 40 Chicago scientists dedicated to translating research into real-world applications.
After spending a combined 50+ years in life sciences in both academia and industry, Steve Kuemmerle and Michael Rosen are helping put Rosalind Franklin on the bioscience industry map with a new state-of-the-art research park slated to open this...
Lynn O'Connor Vos, CEO of Muscular Dystrophy Association, discusses its role as both traditional backer of research and now as aggregator of genetic and clinical data that can help uncover new treatments
For the past 17 years, Bruce Bloom, MD, CEO of Cures within Reach, has been proselytizing the virtues of drug repurposing while helping to advance treatments for more than a dozen diseases. Here's why drug repurposing can be a cheaper, faster and...